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Patients	 with	 severe	 VKA-	associated	 bleeding	 require	 immedi-
ate	 restoration	of	 haemostasis	 by	 reversing	 the	 anticoagulant	 effect	
of	VKA	as	part	of	the	bleeding	management.1	The	first	step	in	rever-
sal	 is	 usually	vitamin	K	 administration.7,8	 Intravenously	 administered	



















rent	 studies	 testing	 antidotes	 for	 the	 direct	 oral	 anticoagulants,18,19 
this	 classification	 scheme	 is	 standardly	 used	 to	 assess	 haemostatic	
efficacy	 of	 the	 reversal	 agent.	 Both	 the	 FDA	 and	 the	 European	
Medicines	 Agency	 (EMA)	 have	 accepted	 this	 standard	 for	 ongoing	
and	future	studies.	This	endpoint	was	not	used	previously	in	studies	







2.1 | Study design and study population
We	performed	a	retrospective	cohort	study	of	consecutive	patients	
who	received	PCC	for	a	VKA-	associated	bleeding	between	September	
































Sarode	 et	al.	 criteria,17	 based	 on	Dutch	 clinical	 practice.	 Haemostatic	
efficacy	was	classified	as	excellent,	good,	or	poor	 for	different	bleed-











clinical	 practice	 policy,	 surrogate	 outcome	 categories	 for	 haemostatic	
efficacy	 (“surrogate	efficacy”)	 in	 ICH	patients	were	set.	Patients	were	
first	classified	as	stable	neurological	condition	since	admission,	cessation	
of	 further	medical	 treatment	due	 to	a	poor	neurological	 condition,	or	
no	records	available.	The	category	“stable	neurological	condition	since	









2.2.2 | Clinical presentation and course
















and	 variability.	 Categorical	 variables	 are	 presented	 as	 proportions	
(n/N)	 and	 percentage	 (%).	 Comparisons	 between	 patients	 from	 the	
different	centers	were	made	using	the	one-	way	analysis	of	variance	
(ANOVA)	 for	 continuous	 variables,	 and	 by	 Chi-	square	 test	 for	 cat-
egorical	 variables.	 A	P-	value	 of	 less	 than	 .05	was	 considered	 to	 be	


















































NSAIDs,	 non-	steroidal	 anti-	inflammatory	 drugs;	 SD,	 standard	 deviation;	
VKA,	vitamin	K	antagonist.
aData	missing	for	17	males	and	18	females.
80  |     BREKELMANS Et AL.















3.2 | Treatment of VKA- related bleedings
The	median	dose	of	administered	PCC	was	2000	international	units	

























ICH	without	haemostatic	efficacy	assessment	 (32	 [78%]).	Of	 the	32	
ICH	patients,	20	(63%)	were	classified	as	having	a	stable	neurological	
condition	 since	admission,	10	 (31%)	 as	 cessation	of	 further	medical	
treatment	due	to	poor	neurological	condition,	and	two	(6%)	as	no	re-
cords	available	(Table	3).
Total cohort N = 100 ICH N = 41 GI bleeds N = 36 Other bleeds N = 23
Dose	of	PCC	administered	in	IU
Males,	median	(IQR) 2000	(1500-	2250) 2000	(1750-	2500) 2000	(1500-	2250) 1750	(1125-	1750)
Females,	median	(IQR) 1500	(1000-	1750) 1500	(1250-	2000) 1250	(1000-	1500) 1250	(1000-	2000)
Dose	of	PCC	in	IU	per	kg,	median	(IQR)
Males 25	(20-	25) 25	(22-	26) 25	(28-	26) 23	(18-	26)
Females 22	(16-	28) 21	(12-	29) 22	(14-	29) 20	(10-	25)
Other	medical	treatment,	n	(%)
Vitamin	K 79	(79) 34	(83) 25	(69) 20	(87)
Tranexamic	acid 4	(4) 1	(2) 1	(3) 2	(9)
Administration	of	blood	products,	n	(%)
Red blood cells 45	(45) 2	(5) 28	(78) 15	(65)
Platelets 6	(6) 4	(10) 2	(6) 0
Fresh	frozen	plasma 8	(8) 1	(2) 5	(14) 2	(9)
Procedures	to	control	the	bleeding,	
n	(%)
39	(39) 12	(29) 21	(58) 6	(26)
Type	of	procedure,	n/N	(%)
Surgical 15/39	(38) 12/12	(100) 0 3/6	(50)
Endoscopic 21/39	(54) 0 20/21	(95) 1/6	(17)

















istration	was	available	 for	61	 (94%)	patients	 and	was	≤1.4	 in	40	
of	61	 (66%)	within	 the	hour.	For	patients	with	poor	haemostatic	











Thromboembolic	 complications	 were	 reported	 in	 5	 (5%)	 patients	
(Table	4).	 Four	 of	 these	 were	 venous	 thromboembolic	 events.	
Eleven	 (11%)	 patients	 had	 a	 new	 bleeding	 complication	 within	
30	days	 after	 the	 VKA	 associated	 bleeding	 event.	 Most	 of	 these	
were	re-	bleedings	at	the	same	location	as	the	initial	bleeding	event.
By	 day	 30	 after	 PCC	 administration,	 22	 (22%)	 deaths	 were	





myocardial	 infarction.	 The	 median	 duration	 of	 hospital	 stay	 was	
7	days,	and	21%	of	patients	was	admitted	in	the	ICU	for	a	median	
of	3	days.
3.3.4 | Clinical presentation and course
Figure	1	details	the	results	of	the	classification	of	the	VKA-	associated	




a	 bleeding	 event	 that	was	 fatal	 before	 or	 almost	 immediately	 after	
entering	the	hospital	(category	4).
The	 clinical	 course	 of	 VKA-	associated	 major	 bleeding	 events	











































ICU,	 intensive	care	unit;	 IQR,	 interquartile	range;	TIA,	transient	 ischemic	
attack;	VKA,	vitamin	K	antagonist.














In	 a	 previously	 published	 randomized	 controlled	 trial,	 PCC	was	
compared	to	plasma	for	immediate	reversal	of	VKA-	associated	major	
bleedings.17	In	that	study,	effective	haemostasis	was	achieved	in	72%	




The	 rapid	 and	 almost	 complete	 INR	 normalization	 observed	 in	
the	 current	 analysis	 is	 consistent	with	 findings	 from	 previous	 stud-
ies.3,17,24–27	In	addition,	the	reported	TE	event	rate	(5%)	is	comparable	





observed	mortality	 rate	was	 22%.	This	 rate	was	 similar	 to	 numbers	
reported	(25%)	in	a	recent	systematic	review	of	PCC,25 but somewhat 
higher	than	in	other	studies	(range	5.8-	7.8%).17,30	The	high	mortality	
rate	 in	 this	 study	 can	be	explained	by	 the	 large	number	of	patients	
included	with	ICH	compared	to	other	studies,	reflecting	the	presence	
of	severe	bleeding	complications	of	VKA	treatment.
Strengths	 of	 the	 present	 study	 include	 consecutive	 sampling,	
the	 relative	 homogeneous	 population	 of	 patients	with	VKA-	related	
bleeding	events	 that	were	 all	 treated	with	PCC,	 the	 representative-
ness	of	the	patients	from	daily	practice,	the	comprehensive	and	stan-





Some	methodological	 aspects	of	 our	 study	 require	 further	 com-
ment.	First,	no	repeat	CT	scan	after	reversal	with	PCC	was	performed	
in	almost	80%	of	patients	with	ICH.	This	is	explained	by	local	treatment	





























repeat	 CT,	 prospective	 and	 possibly	 interventional	 data	 on	 efficacy	
are	needed.	Furthermore,	 this	 study	had	a	small	 sample	size	of	100	
patients	which	might	have	influenced	the	results;	possible	existing	dif-




















































associated	 bleeding	 complications.	 The	 most	 frequently	 observed	
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